Literature DB >> 16139134

Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study.

Cathrine Wold Knudsen1, Torbjørn Omland, Paul Clopton, Arne Westheim, Alan H B Wu, Philippe Duc, James McCord, Richard M Nowak, Judd E Hollander, Alan B Storrow, William T Abraham, Peter A McCullough, Alan Maisel.   

Abstract

OBJECTIVES: This study was designed to assess the diagnostic performance of B-type natriuretic peptide (BNP) in the diagnosis of acute congestive heart failure (CHF) in patients with permanent/paroxysmal atrial fibrillation (AF) presenting with acute dyspnea.
BACKGROUND: It is unknown to what extent AF affects the diagnostic performance of BNP in patients presenting with acute dyspnea.
METHODS: We studied 1,431 patients drawn from a cohort of patients (n = 1,586) with acute dyspnea who had BNP levels measured on arrival. Patients were prospectively classified according to the presence or absence of permanent/paroxysmal AF.
RESULTS: In total, 292 patients had permanent/paroxysmal AF. In patients without HF, permanent/paroxysmal AF was associated with significantly higher BNP levels (p = 0.001). Conversely, in patients with HF, BNP levels did not differ significantly between patients with and without AF (p = 0.533). A BNP cutoff value of 100 pg/ml had a specificity of 40% and 79% for the diagnosis of acute HF in patients with and without AF, respectively. The areas under the receiver-operating characteristic curves were 0.84 (95% confidence interval 0.78 to 0.89) and 0.91 (95% confidence interval 0.89 to 0.93) for patients with and without AF, respectively.
CONCLUSIONS: In patients without, but not in those with HF, the presence of AF is associated with higher circulating BNP levels, suggesting that a higher diagnostic threshold should be used in patients with AF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139134     DOI: 10.1016/j.jacc.2005.05.057

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  35 in total

Review 1.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

2.  Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation.

Authors:  Tsuneaki Sadanaga; Shun Kohsaka; Hideo Mitamura; Satoshi Ogawa
Journal:  Heart Vessels       Date:  2010-12-25       Impact factor: 2.037

Review 3.  Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence.

Authors:  Stephen A Hill; Ronald A Booth; P Lina Santaguida; Andrew Don-Wauchope; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Robert McKelvie; Cynthia Balion; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 4.  Screening for ventricular remodeling.

Authors:  Douglas S Lee; Thomas J Wang; Ramachandran S Vasan
Journal:  Curr Heart Fail Rep       Date:  2006-04

5.  Carotid-femoral pulse wave velocity is associated with N-terminal pro-B-type natriuretic peptide level in patients with atrial fibrillation.

Authors:  Lin Y Chen; Bee C Tai; David C Foo; Raymond C Wong; A Selcuk Adabag; David G Benditt; Lieng H Ling
Journal:  Heart Asia       Date:  2011-01-01

6.  Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Authors:  Stephen J Greene; Gregg C Fonarow; Scott D Solomon; Haris P Subacius; Andrew P Ambrosy; Muthiah Vaduganathan; Aldo P Maggioni; Michael Böhm; Eldrin F Lewis; Faiez Zannad; Javed Butler; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2016-10-17       Impact factor: 15.534

7.  Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Authors:  Borut Jug; Miran Sebestjen; Miso Sabovic; Maja Pohar; Irena Keber
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 8.  Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure.

Authors:  A Palazzuoli; M Gallotta; I Quatrini; R Nuti
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

9.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

10.  Characteristics of acute congestive heart failure with normal ejection fraction and less elevated B-type natriuretic peptide.

Authors:  Ken Shimamoto; Natsuha Koike; Kiyoko Mizuochi; Miho Honma; Yufuko Kasai; Akiko Sakai; Etsuko Fujita; Masatoshi Kawana
Journal:  BMC Cardiovasc Disord       Date:  2009-01-24       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.